BR0316895A - Composto, processo para a preparação do composto, composição farmacêutica, novos intermediários, processo para a preparação dos novos intermediários e uso do composto - Google Patents
Composto, processo para a preparação do composto, composição farmacêutica, novos intermediários, processo para a preparação dos novos intermediários e uso do compostoInfo
- Publication number
- BR0316895A BR0316895A BR0316895-6A BR0316895A BR0316895A BR 0316895 A BR0316895 A BR 0316895A BR 0316895 A BR0316895 A BR 0316895A BR 0316895 A BR0316895 A BR 0316895A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparation
- new intermediates
- pharmaceutical composition
- intermediates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
Abstract
"COMPOSTO, PROCESSO PARA A PREPARAçãO DO FARMACêUTICA, NOVOS INTERMEDIáRIOS, PROCESSO PARA A PREPARAçãO DOS NOVOS INTERMEDIáRIOS E USO DO COMPOSTO". A presente invenção refere-se a novos indolos substituídos de tetracíclicos 3-substituídos, representados pela fórmula geral (I), aos seus estereoisómeros, aos seus radio isótopos, aos seus óxidos de N, aos seus polimorfos, aos seus sais farmaceuticamente aceitáveis, aos seus solvatos farmaceuticamente aceitáveis, aos seus metabólitos bio ativos úteis e a qualquer combinação dos acima mencionados assim como aos processos para a preparação de tais compostos da fórmula geral (I, dos seus estereoisómeros, dos seus radio isótopos, dos seus óxidos de N, dos seus polimorfos, dos seus sais farmaceuticamente aceitáveis, dos seus solvatos farmaceuticamente aceitáveis, dos seus metabólitos bio ativos úteis e também inclui qualquer combinação adequada dos acima mencionados.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN951/MAS/2002 | 2002-12-18 | ||
| IN951MA2002 | 2002-12-18 | ||
| PCT/IN2003/000393 WO2004055026A1 (en) | 2002-12-18 | 2003-12-16 | Tetracyclic 3-substituted indoles having serotonin receptor affinity |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BR0316895A true BR0316895A (pt) | 2005-10-25 |
| BRPI0316895B1 BRPI0316895B1 (pt) | 2018-07-24 |
| BRPI0316895B8 BRPI0316895B8 (pt) | 2019-09-03 |
| BRPI0316895C1 BRPI0316895C1 (pt) | 2021-05-25 |
Family
ID=40848934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0316895A BRPI0316895C1 (pt) | 2002-12-18 | 2003-12-16 | composto, processo para a preparação do composto, composição farmacêutica e uso do composto |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7781476B2 (pt) |
| EP (1) | EP1581538B1 (pt) |
| JP (1) | JP4571507B2 (pt) |
| KR (1) | KR100739987B1 (pt) |
| CN (1) | CN100378109C (pt) |
| AT (1) | ATE355292T1 (pt) |
| AU (1) | AU2003292510B2 (pt) |
| BR (1) | BRPI0316895C1 (pt) |
| CA (1) | CA2507923C (pt) |
| DE (1) | DE60312226T2 (pt) |
| DK (1) | DK1581538T3 (pt) |
| EA (1) | EA009367B1 (pt) |
| HK (1) | HK1083840A1 (pt) |
| MX (1) | MXPA05005808A (pt) |
| NO (1) | NO334030B1 (pt) |
| NZ (1) | NZ540841A (pt) |
| PT (1) | PT1581538E (pt) |
| SI (1) | SI1581538T1 (pt) |
| WO (1) | WO2004055026A1 (pt) |
| ZA (1) | ZA200504042B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005005439A1 (en) * | 2003-07-09 | 2005-01-20 | Suven Life Sciences Limited | Benzothiazino indoles |
| DK1704154T3 (da) | 2004-01-02 | 2009-08-31 | Suven Life Sciences Ltd | Nye indeno(2,1-A)indener og isoindol(2,1-A)indoler |
| WO2006095360A1 (en) | 2005-03-08 | 2006-09-14 | Suven Life Sciences Limited | Process for preparing substituted benzothiazinoindoles |
| NZ566495A (en) | 2005-08-12 | 2010-06-25 | Suven Life Sciences Ltd | Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands |
| US7923566B2 (en) | 2005-08-16 | 2011-04-12 | Suven Life Sciences Limited | Alternative process for the preparation of losartan |
| PL2114878T3 (pl) | 2007-01-08 | 2011-05-31 | Suven Life Sciences Ltd | Związki 5-(heterocyklilo)alkilo-N-(arylosulfonylo)indolowe i ich zastosowanie jako ligandy 5-HT6 |
| ATE513810T1 (de) | 2007-05-03 | 2011-07-15 | Suven Life Sciences Ltd | Aminoalkoxy-aryl-sulfonamidverbindungen und ihre verwendung als 5-ht6-liganden |
| US7807705B2 (en) | 2007-05-18 | 2010-10-05 | The Ohio State University Research Foundation | Potent indole-3-carbinol-derived antitumor agents |
| ES2370680T3 (es) * | 2007-10-26 | 2011-12-21 | Suven Life Sciences Limited | Compuestos de aminoarilsulfonamida y su empleo como ligandos de 5-ht6. |
| WO2010032257A1 (en) | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands |
| ES2424036T3 (es) | 2008-09-17 | 2013-09-26 | Suven Life Sciences Limited | Compuestos de amina de arilsulfonamida y su uso como ligandos de 5-HT6 |
| US8153680B2 (en) | 2009-08-25 | 2012-04-10 | The Ohio State University Research Foundation | Alkyl indole-3-carbinol-derived antitumor agents |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| HUE036008T2 (hu) * | 2013-12-02 | 2018-06-28 | Suven Life Sciences Ltd | Eljárás 1-[(2-brómfenil)szulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)metil]-1H-indol-dimezilát-monohidrát nagyüzemi léptékben történõ elõállítására |
| CN106794170A (zh) * | 2014-08-16 | 2017-05-31 | 苏文生命科学有限公司 | 1‑[(2‑溴苯基)磺酰基]‑5‑甲氧基‑3‑[(4‑甲基‑1‑哌嗪基)甲基]‑1h‑吲哚二甲磺酸盐一水合物的活性代谢物和活性代谢物的二甲磺酸二水合物盐 |
| NZ761037A (en) * | 2017-07-03 | 2022-10-28 | Suven Life Sciences Ltd | New uses of a pure 5-ht6 receptor antagonist |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3487091A (en) * | 1967-12-18 | 1969-12-30 | American Home Prod | 1-(benzyl- or substituted-benzyl)-3-(2-substituted-ethyl) indoles |
| BE889931A (fr) * | 1980-08-12 | 1982-02-11 | Glaxo Group Ltd | Derives indoliques, leur preparation et leurs applications en tant que medicaments |
| GB8600397D0 (en) * | 1986-01-08 | 1986-02-12 | Glaxo Group Ltd | Chemical compounds |
| GB8719167D0 (en) | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
| GB8724912D0 (en) | 1987-10-23 | 1987-11-25 | Wellcome Found | Indole derivatives |
| GB8819024D0 (en) | 1988-08-10 | 1988-09-14 | Glaxo Group Ltd | Chemical compounds |
| IL96891A0 (en) | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
| CA2042295A1 (fr) | 1990-05-15 | 1991-11-16 | Jacques Chauveau | Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant |
| RU2160736C2 (ru) | 1990-06-07 | 2000-12-20 | Зенека Лимитед | Производные индола и их физиологически приемлемые соли и сольваты, способы их получения, лекарственное средство для лечения или профилактики клинических состояний, для которых показан прием агониста "5-нт1-подобного" рецептора, и способ его получения |
| CZ283018B6 (cs) | 1991-02-01 | 1997-12-17 | Merck Sharp And Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi |
| GB9113802D0 (en) | 1991-06-26 | 1991-08-14 | Smithkline Beecham Plc | Medicaments |
| GB9210400D0 (en) | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
| KR940007001A (ko) | 1992-09-16 | 1994-04-26 | 최승주 | 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제 |
| FR2737220B1 (fr) | 1995-07-24 | 1997-09-26 | Adir | Sequences nucleiques codant pour des recepteurs de la melatonine et leurs applications |
| JP2000026471A (ja) * | 1998-07-10 | 2000-01-25 | Nippon Soda Co Ltd | １１−ホルミル−インドロ［１，２−ｂ］［１，２］ベンズイソチアゾールおよび農園芸用殺菌剤 |
| GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| ES2260958T3 (es) * | 1998-12-11 | 2006-11-01 | Virginia Commonwealth University | Ligandos selectivos del receptor 5 - ht 6. |
| US6403808B1 (en) * | 1999-12-10 | 2002-06-11 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
| IL130169A (en) | 1999-05-27 | 2006-08-20 | Neurim Pharma 1991 | Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them |
| FR2799757B1 (fr) * | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN1317276C (zh) * | 2000-09-29 | 2007-05-23 | 中国科学院上海药物研究所 | 一类吲哚基哌啶类化合物及其制备方法和用途 |
| CA2429605A1 (en) * | 2000-11-20 | 2002-05-30 | Scios Inc. | Indol derivative and their use as inhibitors of p38 kinase |
| FR2821843B1 (fr) * | 2001-03-12 | 2003-05-09 | Servier Lab | Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU2003244452A1 (en) | 2002-02-05 | 2003-09-02 | Glaxo Group Limited | Method of promoting neuronal growth |
| CA2490254C (en) * | 2002-06-21 | 2011-11-01 | Suven Life Sciences Limited | Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| DK1537113T5 (da) * | 2002-06-21 | 2011-01-10 | Suven Life Sciences Ltd | Arylalkylindoler med serotoninreceptoraffinitet anvendelige som terapeutiske midler, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse |
| BRPI0315958B8 (pt) * | 2002-11-28 | 2021-05-25 | Suven Life Sciences Ltd | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto |
-
2003
- 2003-12-16 PT PT03768092T patent/PT1581538E/pt unknown
- 2003-12-16 US US10/539,262 patent/US7781476B2/en not_active Expired - Fee Related
- 2003-12-16 KR KR1020057010266A patent/KR100739987B1/ko active IP Right Grant
- 2003-12-16 CN CNB2003801070251A patent/CN100378109C/zh not_active Expired - Fee Related
- 2003-12-16 MX MXPA05005808A patent/MXPA05005808A/es active IP Right Grant
- 2003-12-16 SI SI200330795T patent/SI1581538T1/sl unknown
- 2003-12-16 BR BRPI0316895A patent/BRPI0316895C1/pt not_active IP Right Cessation
- 2003-12-16 CA CA002507923A patent/CA2507923C/en not_active Expired - Fee Related
- 2003-12-16 EP EP03768092A patent/EP1581538B1/en not_active Expired - Lifetime
- 2003-12-16 WO PCT/IN2003/000393 patent/WO2004055026A1/en active IP Right Grant
- 2003-12-16 DK DK03768092T patent/DK1581538T3/da active
- 2003-12-16 AU AU2003292510A patent/AU2003292510B2/en not_active Ceased
- 2003-12-16 DE DE60312226T patent/DE60312226T2/de not_active Expired - Lifetime
- 2003-12-16 NZ NZ540841A patent/NZ540841A/en not_active IP Right Cessation
- 2003-12-16 AT AT03768092T patent/ATE355292T1/de active
- 2003-12-16 EA EA200500994A patent/EA009367B1/ru not_active IP Right Cessation
- 2003-12-16 JP JP2004560176A patent/JP4571507B2/ja not_active Expired - Fee Related
-
2005
- 2005-06-15 NO NO20052909A patent/NO334030B1/no not_active IP Right Cessation
-
2006
- 2006-01-26 ZA ZA200504042A patent/ZA200504042B/en unknown
- 2006-03-30 HK HK06103973A patent/HK1083840A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0316895A (pt) | Composto, processo para a preparação do composto, composição farmacêutica, novos intermediários, processo para a preparação dos novos intermediários e uso do composto | |
| BR0315959A (pt) | Composto, composição farmacêutica uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto | |
| BR0112756A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto | |
| BR0112292A (pt) | Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto | |
| MY130803A (en) | New quinuclidine amide derivatives | |
| BR0009083B1 (pt) | derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida. | |
| EE200200017A (et) | Kinuklidiinderivaadid, nende valmistamismeetod, vaheühendid, farmatseutiline kompositsioon ja nendekasutamine | |
| BR0315681A (pt) | Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável | |
| BRPI0407508B8 (pt) | compostos derivados de bifenila, composição farmacêutica e uso dos mesmos | |
| BR0209580A (pt) | Derivados de ciclohexan-1, 4 diamina substituìdos | |
| BR0311541A (pt) | indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas | |
| DE60215000D1 (de) | DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN | |
| NO329884B1 (no) | Indolderivater, farmasoytisk formulering, anvendelse av forbindelsene, fremgangsmate for fremstilling derav samt mellomprodukter for anvendelse i fremgangsmaten | |
| EA200200291A1 (ru) | Производные биариловых эфиров, полезные в качестве ингибиторов обратного захвата моноамина | |
| BRPI0516003A (pt) | composto, uso em um composto ou um éster, um sal farmaceuticamente aceitável ou um hidrato do mesmo, formulação farmacêutica, e, método para a triagem in vitro de ligandos de receptor de prostanóide seletivos | |
| NO20061737L (no) | Aminosubstituerte erylamino B2 adrenergiske receptoragonister | |
| BRPI0412695A (pt) | derivados de quinolina e quinazolina dotados de afinidade para receptores do tipo 5ht1 | |
| BRPI0417717A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| EA200300183A1 (ru) | Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции | |
| BR0008753B1 (pt) | Composto de amida, processo para preparar um composto de amida, composição farmacêutica e uso de um composto de amida | |
| DK1212320T3 (da) | Phenylpiperazinderivater som inhibitorer for genoptag af serotonin | |
| KR970701544A (ko) | 5-HT_2 길항제를 사용하는 강박반응의 치료법(Treatment of obsessive-compulsive disorders with 5-HT_2 antagonists) | |
| DE60302157D1 (de) | Opioidrezeptorantagonisten | |
| BRPI0517100A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para preparar um composto, composição farmacêutica, e, métodos para tratar um paciente sofrendo de distúrbios e de deficiência | |
| EE200100328A (et) | Antihistamiinsed spiroühendid, vaheühendid ja farmatseutiline kompositsioon ning nende valmistamismeetodid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/07/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/07/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2481 DE 24/07/2018, QUANTO AO ITEM (54) TITULO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2649 DE 13-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |